Established safety and tolerability at 52 weeks with GEMTESA1,2
Adverse reactions reported in ≥2% of patients treated with
GEMTESA 75 mg for up to 52 weeks1,2
|NUMBER OF PATIENTS||273|
|URINARY TRACT INFECTION||18 (6.6%)|
Adverse reactions reported in ≥2% of patients treated with GEMTESA 75 mg for up to 52 weeks in the long-term extension study, and not already listed in the 12-week adverse events table, were urinary tract infection and bronchitis.1
References: 1. GEMTESA Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Data on file, Urovant Sciences GmbH.